section name header

Use and Dosing

Adult Dosingnavigator.gif

Treatment of thrombocythemia associated with myeloproliferative disorders

Pediatric Dosingnavigator.gif

Treatment of thrombocythemia associated with myeloproliferative disorders

7-14 yrs


[Outline]

Indications

Note: Typically, platelet count begins to respond within 7 to 14 days at the proper dosage

Contraindications

Black Box Warnings

Dosing Adjustment

Renal Dose Adjustment

Hepatic Dose Adjustment

Warnings/Precautions

Cautions: Use cautiously in

Interactions

Agrylin interacts with :

significance_3.gifSmoking

Pregnancy/Breast Feeding

Pregnancy Category:C

Breastfeeding: Safety unknown. Manufacturer recommends discontinuation of breastfeeding, or discontinuation of treatment (taking into account the importance of the drug to the mother).

Adverse Reactions

Clinical Pharmacology

Brands and Availability

flag_usa32.png

US Trade Name(s)

US Availability

anagrelide (generic)

Agrylin

flag_canada32.png

Canadian Trade Name(s)

Canadian Availability

anagrelide (generic)

Agrylin

flag_uk32.png

UK Trade Name(s)

UK Availability

Xagrid

flag_australia32.png

Australian Trade Name(s)

Australian Availability

Agrylin


[Outline]

flag_usa32.pngflag_canada32.pngflag_uk32.pngflag_australia32.png

Classification

Hematology/Oncology

Antiplatelet Agents

Pricing

Pricing data from www.DrugStore.com in U.S.A.

Warning.gifWarning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Pill